Analystreport

Summit Therapeutics (SMMT) is now covered by Stifel Nicolaus. They set a "buy" rating and a $45.00 price target on the stock.

Summit Therapeutics Inc.  (SMMT) 
Last summit therapeutics inc. earnings: 6/12 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: summitplc.com/investors/investor-centre